LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-15 and is reviewed periodically as new material appears.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Reconstitution practices affect downstream measurements. The dry powder is typically dissolved in sterile water or a suitable aqueous buffer, then mixed gently rather than vortexed at high speed. Visible particles or cloudiness suggest incomplete dissolution or contamination and should be investigated. For long-term storage, aliquots should be labeled with concentration, solvent, and date. Open questions include how different buffers alter peptide conformation and whether specific container materials adsorb the peptide. Those variables can change apparent concentration in assays even when the chemical identity is correct.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
=== Enhanced oil recovery and carbon capture and storage === Supercritical carbon dioxide is used to enhance oil recovery in mature oil fields. At the same time, there is the possibility of using "clean coal technology" to combine enhanced recovery methods with carbon sequestration. The CO2 is separated from other flue gases, compressed to the supercritical state, and injected into geological storage, possibly into existing oil fields to improve yields. At present, only schemes isolating fossil CO2 from natural gas actually use carbon storage, (e.g., Sleipner gas field), but there are many plans for future CCS schemes involving pre- or post-combustion CO2. There is also the possibility to reduce the amount of CO2 in the atmosphere by using biomass to generate power and sequestering the CO2 produced.
Inflammatory myopathies: polymyositis, dermatomyositis, inclusion body myositis, viral (HIV) Infectious myopathies Endocrine myopathies: thyroid, parathyroid, adrenal, pituitary disorders Toxic myopathies: alcohol, corticosteroids, narcotics, colchicines, chloroquine Critical illness myopathy Metabolic myopathies Paraneoplastic myopathy
==== Eliminated in primary ==== William Abel, U.S. Army veteran David Berry, physician Steve Dowell, U.S. Army veteran Edward Ewald, retiree Abhiram Garapati, real estate investor Valentina Gomez, financial strategist and candidate for Missouri Secretary of State in 2024 (previously ran in the 2nd district) Raymond Hamden, real estate broker Elvis Lossa, policy coordinator Vince Offer, pitchman and comedian
In April 2023, President Lula began his four-day trip during which he called Portugal relations with Brazil "extraordinary" and stated that "Portugal is not simply a foreign country but our home extension". In the 13th Brazil-Portugal Summit the countries signed several agreements such as a mutual recognition of professional degrees, driver's licenses, rights of persons with disabilities and a witness protection programme in both countries. Other agreements signed during the visit include education, science, tourism, energy and audiovisual areas. Lula also attended a high-level Brazilian-Portuguese business meeting in Matosinhos in which Brazilian aerospace giant Embraer and four Portuguese companies (OGMA, EMPORDEF, GMVIS Skysof and CEiiA) announced a deal to build a Brazilian-designed aircraft. Also in the meeting, Prime Minister António Costa announced Portugal companies EDP and Galp will be investing a total of €5.7 billion in projects in Brazil over the next years. On 24 April, Lula took part in a ceremony at the Queluz Palace to award Brazilian singer and songwriter Chico Buarque the Camões Prize.
Sources: en.wikipedia.org
Gearbox announced the formation of Gearbox Studios as a third company under the Gearbox Entertainment Company on October 6, 2021, to oversee television and film productions, with Pitchford serving as Gearbox Studios president alongside as president and CEO of the parent company. Former CTO Steve Jones was named as president of Gearbox Software in Pitchford's place. Embracer announced it intent to acquire Perfect World Entertainment in December 2021 and placing the group, including its publishing arm and Cryptic Studios, under the Gearbox Entertainment operating group. Following its acquisition in April 2022, Perfect World Entertainment was rebranded as Gearbox Publishing San Francisco, with the naming to be applied retroactively to past games published under Perfect World. In April 2022, Gearbox Entertainment announced it will acquire Lost Boys Interactive, which had supported Gearbox in Tiny Tina's Wonderlands. Later that November, Gearbox acquired the Risk of Rain IP from Hopoo Games, while Embracer transferred ownership of Volition to Gearbox Entertainment from Deep Silver following poor reception to its Saints Row reboot. The studio would later shut down the following year due to the restructuring of Embracer Group. That same month, Eidos Shanghai, another studio under the Embracer Group, was transferred to Gearbox Publishing San Francisco and rebranded as Gearbox Studio Shanghai. Gearbox Entertainment acquired Captured Dimensions, a 3D modeling company from Texas, in January 2023.
=== Cardiovascular === Adropin also appears to have cardiovascular effects. It has been implicated in the regulation of endothelial function, which is essential for maintaining blood vessel health. Dysfunction in endothelial cells can contribute to conditions such as atherosclerosis and hypertension. Some studies suggest that adropin may have a protective role in cardiovascular health by promoting the dilation of blood vessels and reducing oxidative stress. In mice, adropin regulates cardiac energy metabolism and improves cardiac function and efficiency. In rats, adropin treatment alleviated diabetes related myocardial fibrosis and diastolic dysfunction, and enhanced the therapeutic potential of mesenchymal stem cells in myocardial infarction.
The Union Public Service Commission (UPSC) is a constitutional body in India tasked with recruiting officers for All India Services and the Central Civil Services (Group A and B) through various standardized examinations. In 2023, 1.3 million applicants competed for just 1,255 positions. The agency's charter is granted by Part XIV of the Constitution of India, titled Services Under the Union and the States. The commission is mandated by the Constitution for appointments to the services of the Union and All India Services. It is also required to be consulted by the Government in matters relating to appointment, transfer, promotion, and disciplinary matters. The commission reports directly to the President. The commission can advise the Government through the president, although such advice is not binding. Being a constitutional authority, UPSC is amongst the few institutions that function with both autonomy and freedom, along with the country's higher judiciary and lately the Election Commission. The commission is headquartered at Dholpur House in New Delhi, and functions through its secretariat. Established on 1st October 1926 as the Public Service Commission, it was later reconstituted as the Federal Public Service Commission by the Government of India Act 1935, and was later renamed as today's Union Public Service Commission after independence.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.